Natreon, Inc. v. Ixoreal Biomed, Inc., 2017 WL 3131975, No.
16-4735 (D.N.J. Jul. 21, 2017)
Natron sued defendant/counterclaimant/third-party plaintiff SKP
and defendant Ixoreal, alleging false advertising and unfair competition in
connection with an extract used in holistic and alternative medicines: KSM-66,
which is derived from the root of the ashwagandha plant. SKP filed three counterclaims,
alleging that Natreon also engaged in false advertising and unfair competition in
selling its competing product. SKP also filed a complaint against third-party
defendant NutraGenesis. Natreon successfully moved to dismiss SKP’s
Counterclaim for violation of the New Jersey Consumer Fraud Act.
SKP’s counterclaims alleged a number of false statements about Natreon’s product, patent protection, and production processes. In addition, SKP alleged that Natreon tried to recruit SKP into engaging in price collusion and engaged in unfair competition by threatening meritless litigation on several occasions. SKP also alleged that both Natreon and NutraGenesis engaged in deceptive acts in an attempt to obtain confidential information, by posing as prospective customers.
Natreon successfully argued that SKP didn’t allege that it
suffered a consumer-like injury, as required for an NJCFA violation. While neither “the statute nor the New Jersey
Supreme Court has explained with any precision who constitutes a consumer,” the
Third Circuit has advised that “the entire thrust of the [statute] is pointed
to products and services sold to consumers in the popular sense.” Thus, the
NJCFA has only been applied to business entities “who purchase goods and
services for use in their business operations,” as, for example, desk
chairs. The alleged wrongdoing here
wasn’t consumer-oriented and the harm was not consumer-like.
The court also struck SKP’s affirmative defense of failure
to mitigate damages, which wasn’t a recognized defense to a Lanham Act claim or
the coordinate common-law claims.
Posts
No comments:
Post a Comment